Citation: Akshaj Pole, Manjari Dimri, Goberdhan P. Dimri. Oxidative stress, cellular senescence and ageing[J]. AIMS Molecular Science, 2016, 3(3): 300-324. doi: 10.3934/molsci.2016.3.300
[1] | Federica Martorana, Paolo Vigneri, Stefano Sergio Cordio, Concetta Martines, Giuseppe Novello, Marco Maria Aiello, Roberto Bordonaro, Hèctor J. Soto Parra . Efficacy of A Fluoropyrimidine plus Mitomycin C in Pretreated Patients with Metastatic Colorectal Cancer Eligible for Regorafenib: A Retrospective Study. AIMS Medical Science, 2017, 4(4): 456-464. doi: 10.3934/medsci.2017.4.456 |
[2] | Derek A. Corica, Dylan M. Schaap, Trenton G. Mayberry, Braydon C. Cowan, Mark R. Wakefield, Yujiang Fang . New depths: exploring the current landscape of colorectal cancer. AIMS Medical Science, 2025, 12(1): 105-123. doi: 10.3934/medsci.2025008 |
[3] | Catherine M. Albert, Seth Pollack . Immunotherapy for synovial sarcoma. AIMS Medical Science, 2019, 6(3): 191-200. doi: 10.3934/medsci.2019.3.191 |
[4] | Anne A. Adeyanju, Wonderful B. Adebagbo, Olorunfemi R. Molehin, Omolola R. Oyenihi . Exploring the multi-drug resistance (MDR) inhibition property of Sildenafil: phosphodiesterase 5 as a therapeutic target and a potential player in reversing MDR for a successful breast cancer treatment. AIMS Medical Science, 2025, 12(2): 145-170. doi: 10.3934/medsci.2025010 |
[5] | Salma M. AlDallal . Quick glance at Fanconi anemia and BRCA2/FANCD1. AIMS Medical Science, 2019, 6(4): 326-336. doi: 10.3934/medsci.2019.4.326 |
[6] | Vivek Radhakrishnan, Mark S. Swanson, Uttam K. Sinha . Monoclonal Antibodies as Treatment Modalities in Head and Neck Cancers. AIMS Medical Science, 2015, 2(4): 347-359. doi: 10.3934/medsci.2015.4.347 |
[7] | Yuxiang Zou, Jialong Qi, Hui Tang . Regulatory role of FOXQ1 gene and its target genes in colorectal cancer. AIMS Medical Science, 2024, 11(3): 232-247. doi: 10.3934/medsci.2024018 |
[8] | Anuj A. Shukla, Shreya Podder, Sana R. Chaudry, Bryan S. Benn, Jonathan S. Kurman . Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment. AIMS Medical Science, 2022, 9(2): 348-361. doi: 10.3934/medsci.2022016 |
[9] | Kwon Yong, Martin Brechbiel . Application of 212Pb for Targeted α-particle Therapy (TAT): Pre-clinical and Mechanistic Understanding through to Clinical Translation. AIMS Medical Science, 2015, 2(3): 228-245. doi: 10.3934/medsci.2015.3.228 |
[10] | Payal A. Shah, John Goldberg . Novel Approaches to Pediatric Cancer: Immunotherapy. AIMS Medical Science, 2015, 2(2): 104-117. doi: 10.3934/medsci.2015.2.104 |
In the last few years, colon cancer research groups have retrospectively reviewed data from large phase three trials in advanced disease, and made the observation that primary tumour location has an important impact on overall survival. The key finding is that patients with left sided colon cancers (LCC) (from splenic flexure to distal rectum) live considerably longer than patients with right sided colon cancers (RCC) (caecum to splenic flexure). In the CALGB/SWOG 80405 phase 3 trial, median overall survival for LCC of 32.9 months versus 19.6 months for RCC (p < 0.0001) was recorded. Furthermore, retrospective analysis of this study demonstrated that primary tumour location had a significant impact on the response to anti-EGFR targeted therapy in RAS wildtype tumours. The addition to chemotherapy of Cetuximab compared to Bevacizumab significantly prolonged median OS in LCC (39.3 v 32.6 months, HR = 0.77, 95% CI, 0.59-0.99, p < 0.05), but not in RCC (13.7 v 29.2 months, HR = 1.36, 95% CI, 0.93-1.99, p = 0.11, see Table 1) [1]. Although not used prospectively as a means to stratify patients in such clinical trials, the impact of primary tumour location on patient outcomes has been corroborated across the retrospective analysis of several trials (see Table 1). The aetiology of this observation is currently uncertain and under investigation. Furthermore, primary tumour location (PTL) appears to differentially affect the response to therapies such as targeted agents, raising the prospect that PTL could be used as predictive biomarker. The evidence for this will be scrutinised in this review. The current position on this topic is that PTL might actually be a convenient surrogate for another molecular biomarker, and that such knowledge might help to build a new understanding of colon cancer being a cluster of diseases, with divergent clinical outcomes and different responses to therapies.
Trial | Left colon cancer OS (months) |
HR, 95% CI p value |
Right colon cancer OS (months) |
HR, 95% CI p value |
||
CALGB 80405 | Overall pop = 32.9 | Overall pop = 19.6 (p < 0.0001) | ||||
Chemo + Cet | Chemo + Bev | Chemo + Cet | Chemo + Bev | |||
39.3 | 32.6 | 0.77 (0.59-0.99) p = 0.05 |
13.7 | 29.2 | 1.36 (0.93-1.99) p = 0.11 |
|
FIRE-3 | 38.3 | 28.0 | 0.63 (0.48-0.85) p = 0.002 |
18.3 | 23.0 | 1.31 (0.81-2.11) p = 0.27 |
FOLFIRI + Cet | FOLFIRI only | FOLFIRI + Cet | FOLFIRI only | |||
CRYSTAL | 28.7 | 21.7 | 0.65 (0.50-0.86) p = 0.002 |
18.5 | 15.0 | 1.08 (0.65-1.81) p = 0.77 |
FOLFOX + Pani | FOLFOX only | FOLFOX + Pani | FOLFOX only | |||
PRIME | 30.3 | 23.6 | 0.73 (0.57-0.93) p = 0.012 |
11.1 | 15.4 | 0.87 (0.55-1.37) p = 0.55 |
FOLFOX + Pani | FOLFOX + Bev | FOLFOX + Pani | FOLFOX + Bev | |||
PEAK | 43.4 | 32.0 | 0.77 (0.46-1.28) p = 0.31 |
17.4 | 21.0 | 0.67 (0.30-1.50) p = 0.32 |
Cet: Cetuximab; Pani: Panitumumab; Bev: Bevacizumab; OS: Overall survival; HR: Hazard ratio. |
Right-sided colon cancers (RCC) comprise primary tumours located anywhere between the caecum and the distal part of the transverse colon (see Figure 1). For most authors, Left-sided colon cancers (LCC) comprise primary tumours located anywhere between the splenic flexure and the distal rectum. However, some studies have treated rectal cancers as a separate entity, largely because the surgical approach and use of radiotherapy/chemoradiotherapy differs for rectal cancer as compared to colon cancers. Such categorisation follows differences in embryological origin, with the right colon (caecum to two thirds of the transverse colon) deriving from the midgut, and the left colon (splenic flexure to distal rectum) deriving from the hind-gut. Furthermore, the allocation of the transverse colon to either right or left side is not consistent, some studies considering it wholly part of the right side of the colon, whilst others have excluded data relating to the transverse colon [2], acknowledging that its features (blood supply, histology, molecular traits) lie somewhere on a continuum between right and left. In addition, there is recognition by many authors that the correct attribution of tumours to the transverse colon is missing from many studies, owing either to the lack of natural landmarks available during diagnostic endoscopy or to the lack of precise surgical or pathological reporting.
The publication of several large case-series and databases has raised awareness that prognosis was different between patients with right-sided colon cancer (RCC) versus left-sided colon cancer (LCC) (see Table 2) [3,4].
Author | Number of patients | Year of pub. | 5 yr OS (R v L) | Median OS (R v L) in months | Risk of death as HR (95% CI) |
Benedix | 17,000 | 2010 | 67% v 71% (p < 0.01) | ||
Meguid | 78,000 | 2008 | 56% v 60% (p < 0.001) | 78 v 89 (p < 0.001) | 0.96 (0.93-0.99) |
Price | 2,900 | 2015 | 9.6 v 20.3 (p < 0.0001) | ||
Petrelli | 1.4 Million | 2017 | 0.82 (0.79-0.84) |
Differences in histological characteristics, patient age and stage at diagnosis explain some of the observed differences. A large prospective German study in the early 2000s collected data on over 17,000 new colon cancer diagnoses (excluding rectal cancers), which included early and advanced cancer. Patients with RCC were 3 years older than patients with LCC (71 v 68.5 years, p < 0.01), had higher rates of poorly differentiated tumours (Odds Ratio of 1.53, 95% 1.42-1.66, p < 0.01), and in those patients who underwent curative intent primary bowel resection (11,500 patients), higher proportions of American Joint Committee on Cancer (AJCC) stage II (43.1% v 37.8%, p < 0.01%) and stage III (36.1% v 33.6%, p < 0.01%) were seen in RCC compared to LCC. Five-year survival was significantly higher in LCC (71%) compared to RCC (67%) (p < 0.01) [4]. In an analysis of the American Surveillance, Epidemiology and End Results program (SEER) database in the early 2000s comprising nearly 78,000 patients who had undergone colon cancer resections, when controlled for confounders such as age, stage and histological grade, patients with RCC had shorter 5-year OS than LCC (56% v 60%, p < 0.001), with a HR for death of 1.04 (95% CI, 1.02-1.07) [3]. Recent analysis of the South Australian Registry for metastatic colorectal cancer, which includes over 2900 patients, found a statistically different OS between RCC and LCC (9.6 v 20.3 months, p < 0.001). Furthermore, multivariate analysis confirmed that PTL was an independent prognostic marker [5]. A large systematic review and meta-analysis encompassing data from 66 studies and over 1.4 million patients with early and advanced colon cancer found that LCC carried a 19% lower risk of death compared to RCC, with a HR in favour of LCC of 0.82 (95% CI, 0.79-0.84, p < 0.001). Furthermore, PTL was an independent prognostic factor, independent of race, stage (II, III and IV), publication year and type of study (prospective versus retrospective) [6].
These epidemiological findings have also been observed in randomised clinical trials. In 2001, O'Dwyer published randomised evidence of a 5 month difference in survival in patients with advanced colon cancer treated with 5FU favouring left-side as primary tumour location compared to right side, with median OS of 15.8 months for LCC versus 10.9 months for RCC (p < 0.001) [7].
Genetic differences were proposed to exist between RCC and LCC as a consequence of distinct embryology, vascular supply (superior versus inferior mesenteric artery), and microenvironment [8], see Figure 1. Histological subtypes of adenocarcinoma usually associated with poorer prognosis are more common in RCC than LCC, e.g. mucinous (10.6% v 6.3%, p < 0.01%), signet-ring (0.9% v 0.3%, p < 0.01%), and undifferentiated (0.7% v 0.2%, p < 0.01%) [4].
There is a wealth of literature concerning molecular differences between RCC and LCC. Three broad molecular pathways leading to CRC have been described in the literature, including their relationship to primary tumour location: Chromosomal instability (CIN), microsatellite instability (MSI), and CpG island methylator phenotype (CIMP). CIN is more common in LCC than in RCC, with rates of 60% v 20% reported [9]. Microsatellite instability (MSI), which leads to defects in DNA mismatch repair is more prominent in RCC, representing 15-50% of RCC depending on case series [10], compared to LCC, where it arises in less than 5% of cases. In a comprehensive clinicopathological analysis of 734 colorectal cancer specimens from South Korea, the CpG island (hypermethylator) phenotype (CIMP or CIMP+), a condition characterised by the methylation of multiple CpG islands in the promoter region of genes, was found in higher proportions in RCC than LCC, with significant differences in incidence of 16% in RCC, 3% in distal colon, and 2.5% in the rectum (p = 0.001). In the same study, MSI-High status was also more prevalent in RCC v LCC, with significant differences in incidence of 19% in RCC, 7.2% in distal colon, and 2.5% in rectum (p < 0.001) [11,12]. There is a strong correlation between CIMP+ and sporadic colorectal cancers with MSI-High by virtue of the methylation of hMLH1 [13], and the CIMP+ phenotype accounts for almost all cases of BRAF mutated CRC [14], which are far more common in RCC (20-35%) compared to LCC (2-19%) [12]. These molecular traits vary in a linear fashion with frequencies of MSI-High, CIMP+, and BRAF mutations gradually increasing from rectum to ascending colon [12].
More recently, colon cancers have been classified according to molecular subtypes using RNA expression profiling. Various methodologies have been used to formulate different categorizations: The Colorectal Cancer Assigner (CRCA) subtypes (5 subgroups), the Colorectal Cancer Subtypes (CCS, 3 subgroups), and the Consensus Molecular Subtypes (CMS, 4 subgroups) [15,16,17,18,19,20]. The CMS group proposed four subtypes that are labelled CMS1 (called MSI Immune, representing 14% of colorectal cancer cases, mostly MSI tumours, more common in females and in RCC), CMS2 (called Canonical, 37%, mostly LCC with better survival after relapse), CMS3 (called Metabolic, 13%), and CMS4 (called Mesenchymal, 23%, usually diagnosed at higher stage with worse prognosis) [17]. The relationship between these CMS profiles and somatic mutations is not so clear: Although CMS1 tumours were enriched in BRAF mutations and CMS3 tumours were enriched in KRAS mutations, single genomic mutations did not define any of the CMS groups [17]. A correlative study was performed in another series of 608 patients with colorectal cancer between PTL, CMS groups, and mutations in genes such as RAS, BRAF, PIK3CA, and PTEN. CMS profiles showed a decline in CMS1 and CMS3, and a rise CMS2 prevalence moving distally [21]. A similar investigation was performed in an early cancer setting. An analysis of the NSABP/NRG C-07 adjuvant trial demonstrated the benefit of the addition of oxaliplatin to 5FU [22]. In this scenario, neither PTL or CMS were found to be prognostic or predictive of response to oxaliplatin [23]. In a separate study of the same samples, a CRCA subset called stem-like (equivalent to CCS3 or CMS4 in the other classification systems) was found to carry poor prognosis and was not correlated with benefit from oxaliplatin chemotherapy [24]. In patients with RAS-WT metastatic disease, a retrospective analysis of the CALGB/SWOG 80405 data found that patients with CMS1 (mostly RCC patients) benefitted significantly more if they had been randomised to Bevacizumab compared to Cetuximab, whereas a trend towards better outcomes was observed for CMS2 patients if they had been randomised to Cetuximab [25]. Further work is needed to determine if these molecular signatures are predictive of benefit to specific treatments, and also to definitively answer the question as to whether these molecularly-defined subtypes cluster according to sidedness, especially given the real-life advantages of having a cheap and easy predictive biomarker (PTL) versus an expensive and still cumbersome method (RNA expression profiling).
The benefit of adjuvant chemotherapy in stage III colorectal cancer is considered to be independent of location of primary tumour. However, the majority of large randomised trials in this setting have not addressed this question. An appraisal of the SEER database suggests that the benefit of adjuvant chemotherapy is not driven by PTL, with 5-year OS advantage from chemotherapy established for both RCC (HR = 0.64, p < 0.001) and LCC (HR = 0.61, p < 0.001). Retrospective analyses at single institutions suggest that the benefit from adjuvant chemotherapy might be more pronounced for RCC compared to LCC [26]. Microsatellite instability (MSI) or defects in the mismatch repair pathway (dMMR), found in approximately 15% of colorectal cancers, more commonly in RCC v LCC (80% v 20%) [27], contributes to these observations. In the NO147 trial investigating the benefit of Cetuximab added to oxaliplatin-based chemotherapy in the adjuvant treatment of 2,680 patients with stage III colon cancer, proximal dMMR cancers had better DFS compared to proximal proficient MMR tumours (HR = 0.71, 95% CI, 0.53-0.94), whereas for distal cancers, the DFS of deficient versus proficient MMR cases was no different (HR = 1.71, 95% CI, 0.99-2.95) [28]. This raised the question of whether proximal dMMR had better intrinsic prognosis compared to matched proficient MMR tumours or whether they benefited differently from chemotherapy. Retrospective analysis of the QUASAR trial data suggests that early (stage II) dMMR tumours have a good prognosis regardless of adjuvant chemotherapy and indeed, in these cases, the benefit of adjuvant chemotherapy has been called into question [29]. A larger study that included clinicopathological data from several North-American and European adjuvant 5FU-based chemotherapy trials, totalling 2141 patients with stage II and III colon cancer, determined that dMMR was present in 16.1% tumours, and significantly more likely to occur in RCC v LCC (p < 0.001). dMMR was associated with reduced 5-year recurrence compared to pMMR (22% v 33%, p < 0.001), and was independently associated with improved DFS (HR = 0.80, 95% CI, 0.64-0.99, p = 0.035) and OS (HR = 0.79, 95% CI, 0.64-0.99, p = 0.031) [27]. Therefore, it appears that in early colon cancers (Stage II, or Stage III N1 disease), it is not so much the PTL that is prognostic but rather certain molecular makers—in this case dMMR, which happens to occur more frequently in RCC—that determine prognosis.
The key recent finding was that primary tumour location was found to be an independent prognostic marker (independent from Age, Gender, CMS, MSI, BRAF) in a retrospective analysis of patients with advanced colon cancer treated within the large Phase III CALGB/SWOG 80405 trial which compared the efficacy of Cetuximab v Bevacizumab when added to standard 1st line chemotherapy [2,30]. LCC had a median prognosis of 33.3 months versus 19.4 months for patients with RCC (HR = 1.55, 95% CI [1.32-1.82], p < 0.0001).
A retrospective analysis of the phase 2 AIO KRK-1014 trial, in which 400 patients with metastatic colon cancer were randomised to CAPIRI + Cetuximab v CAPOX + Cetuximab indicated the prognostic significance of PTL in patients with KRAS-WT tumours [31]. In the KRAS WT subgroup median OS for LCC was 29 months v 13 months for RCC (HR = 0.42, p < 0.001). Conversely, in patients with KRAS mutations, no significant difference in OS was found between LCC and RCC. Based on these observations, the authors proposed that LCC might be a predictor of Cetuximab efficacy [31]. A similar observation was made in the FIRE-3 trial that randomised 592 patients to FOLFIRI with either Cetuximab or Bevacizumab [32]. In KRAS-WT patients treated with cetuximab, significantly greater efficacy was observed in LCC compared to RCC, with better OS (HR = 0.26), PFS (HR = 0.35), and overall response rate (ORR, HR = 2.7) recorded. The same treatment effect according to PTL was observed in PEAK [33]. In CALCB/SWOG80405, FIRE-3 and PEAK trials, a statistically significant advantage in OS was observed in favour of LCC over RCC across treatment groups (see Table 1).
In all three trials, for LCC, PTL was predictive of benefit to anti-EGFR versus anti-VEGF therapy, with statistically superior OS observed ranging between 6-11 months (apart from PEAK, where the advantage of Panitumumab over Bevacizumab was non-significant). For RCC, in each case, a non-statistically superior advantage of 3-15 months was observed in favour of Bevacizumab therapy (see Table 1). Based on these findings, data was pooled in meta-analyses, where outcomes of patients treated with chemotherapy with Cetuximab versus chemotherapy alone or with Bevacizumab could be analysed according to RCC v LCC. One analysis included six clinical trials (CRYSTAL, FIRE-3, CALGB 80405, PRIME, PEAK and 20050181) [34] where data of 2159 out of 5760 patients is complete for both RAS-WT status and PTL. In LCC, OS analysis showed a statistically significant benefit in favour of the addition of anti-EGFR to chemotherapy (HR 0.75, 95% CI: 0.67-0.84). Crucially, no OS benefit was observed for anti-EGFR in RCC (HR = 1.12, 95% CI: 0.87-1.44). In a separate meta-analysis of the PRIME and CRYSTAL trials [35], an OS advantage was observed for the addition of anti-EGFR MAb in LCC cancers (HR = 0.69, p < 0.0001), but not RCC (HR = 0.96, p = 0.8). The same authors performed a meta-analysis of CALGB/SWOG 80405, FIRE-3, and PEAK, 3 trials that compared anti-EGFR against anti-VEGF when added to chemotherapy, totalling 1011 patients, and found a significant OS advantage in favour of anti-EGFR therapy for LCC (HR = 0.71, p = 0.0003), and a non-significant OS favouring anti-VEGF (HR = 1.3, p = 0.081) for RCC [35].
Retrospective analysis was performed on the efficacy of second line chemotherapy for 70% of patients (n = 411) treated within the FIRE-3 trial who progressed after first line therapy, in whom PTL was known. Comparable frequencies of oxaliplatin, fluoropyrimidines and other respective other antibody (-class) were used in both arms of FIRE-3. For both LCC and RCC, rates of uptake of second line therapy were similar. It was found that efficacy of second line therapy was significantly superior for LCC than for RCC, with longer PFS (6 v 3.8 months, HR = 0.61, 95% CI 0.47-0.78), as well as longer OS for LCC (15.9 v 11.0 months, HR = 0.64, 95% CI 0.49-0.84, p = 0.001). The choice of targeted first-line therapy influenced the PFS and OS of second-line therapy only for LCC, favouring a Cetuximab-Bevacizumab rather than a Bevacizumab-Cetuximab sequence (LCC OS 17.6 v 14.1 months, HR = 0.65, 95% CI 0.49-0.85, p = 0.002; RCC OS 11.0 v 12.4 months, HR = 1.02, 95% CI 0.64-1.61, p = 0.94). The survival differences observed between LCC and RCC and sequencing of biologic agent in this retrospective study were not thought to be due to a cross-over effect, but to be a result of different tumour biology. Furthermore, based on the different survival outcomes of second line therapy observed in this study, as well as the different survival outcomes noted in first-line setting of FIRE-3, the authors have proposed for RAS-WT advanced colorectal cancer an ideal sequencing of targeted therapy favouring anti-EGFR followed by Bevacizumab for LCC versus Bevacizumab followed by anti-EGFR for RCC [36].
Differences in outcomes between RCC and LCC were also observed in the setting of chemotherapy-refractory cancers within the Phase III CO.17 trial. In this trial, patients who had progressed on standard chemotherapy were randomised to Cetuximab or best supportive care (BSC), with overall survival significantly longer in the treatment versus the control arm (6.1 v 4.6 months, HR = 0.77, p = 0.005) [37]. Retrospective survival analysis found that PTL was not a predictor of prognosis (the survival of the BSC group was unaffected by PTL). However, analysis of the Ras-WT subgroup found that PTL was a predictive of a survival advantage from treatment with Cetuximab. For patients with LCC, the cetuximab group had a median overall survival of 10.1 months compared to 4.8 months for the BSC group (p = 0.002). For patients with RCC, a non-significant OS of 6.2 months v 3.5 months (p = 18) was observed [38].
There is limited published data surrounding the predictive impact of PTL on response to bevacizumab. PTL as a predictive marker of benefit from bevacizumab therapy in the setting of first line chemotherapy for metastatic colon cancer has been studied retrospectively in two randomised trials, AVF2107g (Irinotecan-based chemotherapy + Bevacizumab or Placebo) [39], and NO16966 (Oxaliplatin-based chemotherapy + Bevacizumab or placebo) [40], and one prospective pharmacogenetic study (PROVETTA), totalling over 2000 patients, and reported by Loupakis and co-authors [41]. In both randomized studies, PTL was a strong prognostic marker with LCC having better PFS and OS than RCC, but Bevacizumab efficacy was independent of PTL. The effect of PTL on outcomes of patients treated with Bevacizumab was also retrospectively assessed in the randomised Phase III MAX trial, which investigated capecitabine +/− Bevacizumab as 1st line treatment of metastatic colorectal cancer [42]. Data from this trial according to PTL was presented at the ESMO 2014 conference and suggested no difference in benefit between RCC and LCC [43]. The predictive value of PTL was assessed in relation to the benefit of the anti-VEGF inhibitor Aflibercept, when added to second-line FOLFIRI chemotherapy in the VELOUR study, and found not to be predictive of preferential outcomes for either RCC or LCC [44]. Therefore, it appears that based on the published evidence benefit from anti-angiogenic therapy does not depend on PTL.
Immunotherapy is rapidly increasingly important therapy for cancer and is at the forefront of research. This has particularly been the case for Melanoma and Lung Cancer, but evidence for its effectiveness in CRC is still trailing. A potential role for immunotherapy was envisaged for microsatellite unstable (MSI) colon cancers, with increased frequency of mutated cancer epitopes providing a milieu for heightened immunogenicity was put forward as an explanation [45]. Given that MSI CRC is more prominently found in RCC compared to LLC, one expects that successful immunotherapy in CRC might be the preserve of some subtypes (MSI) of metastatic RCC. Phase II data has recently been published demonstrating high response rates (40%) of MSI metastatic colon cancer to treatment with pembrolizumab compared to very low response rates (0%) in MSS colon cancers [46]. Phase III data is awaited to assess the magnitude of therapeutic benefit and also to ascertain whether dMMR will form the basis of a strong predictive biomarker to immunotherapy in colon cancer, and what place PTL might play in this regard. Currently, more mature Phase II data from the same authors, including the use of Pembrolizumab in tumour sites other than colon cancer, suggests that dMMR is a very strong predictive biomarker of response to Pembrolizumab [47]. Concerning the use of such treatment in colon cancers, PTL could not be considered a good predictive biomarker of response to Pembrolizumab, but at best be an incomplete surrogate marker of dMMR.
The question of the prognostic impact of PTL on surgical outcomes of liver metastasectomies has been addressed in several retrospective series [48,49]. The consensus from these publications is that metastatic RCC has worse overall prognosis (worse OS), but that recurrence in the liver following hepatic resection is independent of PTL, whilst extra-hepatic recurrence is more common in rectal cancers. The same question has been posed in the case of pulmonary metastasectomy in a case series involving 698 patients, where lung metastases from rectal cancer were associated with worse 5 year disease-free survival (60.1%) compared to that of patients with lung metastases from colon cancer (67.2%, p = 0.004), even though overall survival was not different (p = 0.545). Owing to small numbers, the colon group was not further subdivided in RCC and LCC. In those patients with rectal cancer who recurred following pulmonary metastasectomy, the most common site of recurrence was lung, whereas for patients with colon cancer it was the liver (p = 0.0001) [50]. These retrospective case series highlight the different preferential locations of metastatic behaviour previously described between RCC and LCC. Although the differences in outcomes observed are insufficient to inform differential management, they identify questions to be tested in clinical trials.
The impact of PTL has also been retrospectively investigated in relation to the effectiveness of selective Internal radiation therapy using yttrium-90 resin microspheres in patients with liver-predominant metastases from colorectal cancer [51]. SIRT did not result in improved survival when combined with chemotherapy in patients with liver-predominant metastatic disease [52]. In the combined analysis of three randomised trials (FOXFIRE, SIRLFOX and FOXFIRE-GLOBAL) that tested the use of mFOLFOX6 chemotherapy +/− SIRT therapy in a total of 1103 patients, no benefit in either median PFS (HR = 0.90; 95% CI 0.79-1.02, p = 0.108) or OS (HR = 1.04, CI 0.90-1.19, p = 0.609, 24.3 months with SIRT v 24.6 months without SIRT, p = 0.24) was found for the addition of SIRT in the overall population. However, when combined data from the SIRFLOX and FOXFIRE-GLOBAL was split according to PTL, a small but significant benefit in OS emerged for RCC as opposed to LCC (22.0 v 17.1 months, HR = 0.67 [0.48-0.92], p = 0.007) [51,53]. This data must be interpreted with caution given relative small numbers of patients and the retrospective nature of the analysis. The biology underpinning this observation is unknown. However this raises the possibility that liver metastases from RCC might respond better to radiotherapy than that those of LCC. Further clinical trials are warranted in this field, either for sole inclusion of RCC, or where PTL forms the basis of an integral pre-specified subgroup analysis.
Primary tumour location has emerged as an interesting prognostic and predictive marker in the therapeutic paradigm of colorectal cancer, particularly for metastatic disease. It has to be noted that the majority of data has been obtained through retrospective analysis of clinical trials and case series where PTL was neither part of the stratification, nor pre-planned subgroup analysis. Despite the caution in interpretation because of risk of recall bias the analyses are consistent in observing the same prognostic effect, with several studies establishing PTL as an independent prognostic marker. Furthermore, the predictive power of Left side in determining extra therapeutic benefit from anti-EGFR treatment is very strong whereas the data presented in this review questions any therapeutic benefit of these drugs in RCC. Our view is that clinicians and patients should carefully discuss the merits of adding anti-EGFR therapy to chemotherapy in metastatic RCC. The prognostic and predictive attributes of PTL add weight to the fact that RCC and LCC have different behaviours and are therefore distinct entities. The question currently is whether LCC and RCC are truly different diseases by virtue of their distinct embryological origins, or whether left and right are surrogate variables for an as yet to be determined molecular signature that predicts different disease behaviour and response to treatment. It is most likely the case that further research and discoveries in molecular subtyping will enable further refinement in the segregation of patients at a prognostic level but also eventually into responders and non-responders to novel therapies. It is also likely that there will be some overlap between this molecular stratification and primary tumour location according to a RCC v LCC dichotomy. Short of possessing a robust molecular stratification system to guide choice of therapy for patients undergoing systemic treatment, segregating patients according to RCC v LCC is a useful and pragmatic approach to guide decision-making regarding biological agents and should be adopted by oncologists in clinical practice. Future clinical trials will benefit from PTL data being prospectively collected and some clinical trials should in our view stratify participants according to PTL. This is particularly the case for clinical trials investigating drugs targeting the EGFR pathway, given the very strong benefit in RAS-WT LCC compared to RCC treated with these agents.
The authors declare no conflict of interest.
PJR has received grant funding from Sanofi, speakers fees from Amgen, Merck-Serono, Servier and Sirtex.
[1] | Harman D (1956) Aging: a theory based on free radical and radiation chemistry. J Gerontol 11: 298-300. |
[2] |
Harman D (2009) Origin and evolution of the free radical theory of aging: a brief personal history, 1954-2009. Biogerontology 10: 773-781. doi: 10.1007/s10522-009-9234-2
![]() |
[3] |
Perez VI, Bokov A, Van Remmen H, et al. (2009) Is the oxidative stress theory of aging dead? Biochim Biophys Acta 1790: 1005-1014. doi: 10.1016/j.bbagen.2009.06.003
![]() |
[4] | Jin K (2010) Modern Biological Theories of Aging. Aging Dis 1: 72-74. |
[5] |
Jacob KD, Hooten NN, Trzeciak AR, et al. (2013) Markers of Oxidant Stress that are Clinically Relevant in Aging and Age-related Disease. Mech Ageing Dev 134: 139-157. doi: 10.1016/j.mad.2013.02.008
![]() |
[6] |
Gruber J, Fong S, Chen C-B, et al. (2013) Mitochondria-targeted antioxidants and metabolic modulators as pharmacological interventions to slow ageing. Biotechnol Adv 31: 563-592. doi: 10.1016/j.biotechadv.2012.09.005
![]() |
[7] | Vallyathan V, Shi X (1997) The role of oxygen free radicals in occupational and environmental lung diseases. Environ Health Perspect 105 Suppl 1: 165-177. |
[8] |
Berneburg M, Gattermann N, Stege H, et al. (1997) Chronically ultraviolet-exposed human skin shows a higher mutation frequency of mitochondrial DNA as compared to unexposed skin and the hematopoietic system. Photochem Photobiol 66: 271-275. doi: 10.1111/j.1751-1097.1997.tb08654.x
![]() |
[9] |
Valko M, Rhodes CJ, Moncol J, et al. (2006) Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact 160: 1-40. doi: 10.1016/j.cbi.2005.12.009
![]() |
[10] |
Ambrose JA, Barua RS (2004) The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol 43: 1731-1737. doi: 10.1016/j.jacc.2003.12.047
![]() |
[11] |
Turrens JF (2003) Mitochondrial formation of reactive oxygen species. J Physiol 552: 335-344. doi: 10.1113/jphysiol.2003.049478
![]() |
[12] |
Schrader M, Fahimi HD (2006) Peroxisomes and oxidative stress. Biochim Biophys Acta 1763: 1755-1766. doi: 10.1016/j.bbamcr.2006.09.006
![]() |
[13] | Cheeseman KH, Slater TF (1993) An introduction to free radical biochemistry. Br Med Bull 49: 481-493. |
[14] |
Krause KH (2007) Aging: a revisited theory based on free radicals generated by NOX family NADPH oxidases. Exp Gerontol 42: 256-262. doi: 10.1016/j.exger.2006.10.011
![]() |
[15] |
Jiang F, Zhang Y, Dusting GJ (2011) NADPH oxidase-mediated redox signaling: roles in cellular stress response, stress tolerance, and tissue repair. Pharmacol Rev 63: 218-242. doi: 10.1124/pr.110.002980
![]() |
[16] |
Manea A (2010) NADPH oxidase-derived reactive oxygen species: involvement in vascular physiology and pathology. Cell Tissue Res 342: 325-339. doi: 10.1007/s00441-010-1060-y
![]() |
[17] |
Takac I, Schroder K, Brandes RP (2012) The Nox family of NADPH oxidases: friend or foe of the vascular system? Curr Hypertens Rep 14: 70-78. doi: 10.1007/s11906-011-0238-3
![]() |
[18] |
Bedard K, Krause KH (2007) The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 87: 245-313. doi: 10.1152/physrev.00044.2005
![]() |
[19] |
Rodriguez-Manas L, El-Assar M, Vallejo S, et al. (2009) Endothelial dysfunction in aged humans is related with oxidative stress and vascular inflammation. Aging Cell 8: 226-238. doi: 10.1111/j.1474-9726.2009.00466.x
![]() |
[20] |
Schroder K, Zhang M, Benkhoff S, et al. (2012) Nox4 is a protective reactive oxygen species generating vascular NADPH oxidase. Circ Res 110: 1217-1225. doi: 10.1161/CIRCRESAHA.112.267054
![]() |
[21] |
Chiu JJ, Chien S (2011) Effects of disturbed flow on vascular endothelium: pathophysiological basis and clinical perspectives. Physiol Rev 91: 327-387. doi: 10.1152/physrev.00047.2009
![]() |
[22] | Montezano AC, Touyz RM (2012) Oxidative stress, Noxs, and hypertension: experimental evidence and clinical controversies. Ann Med 44 Suppl 1: S2-16. |
[23] |
Brand MD, Affourtit C, Esteves TC, et al. (2004) Mitochondrial superoxide: production, biological effects, and activation of uncoupling proteins. Free Radic Biol Med 37: 755-767. doi: 10.1016/j.freeradbiomed.2004.05.034
![]() |
[24] |
Muller FL, Liu Y, Van Remmen H (2004) Complex III releases superoxide to both sides of the inner mitochondrial membrane. J Biol Chem 279: 49064-49073. doi: 10.1074/jbc.M407715200
![]() |
[25] |
Madamanchi NR, Runge MS (2007) Mitochondrial dysfunction in atherosclerosis. Circ Res 100: 460-473. doi: 10.1161/01.RES.0000258450.44413.96
![]() |
[26] | Linnane AW, Marzuki S, Ozawa T, et al. (1989) Mitochondrial DNA mutations as an important contributor to ageing and degenerative diseases. Lancet 1: 642-645. |
[27] | Lee HC, Wei YH (2007) Oxidative stress, mitochondrial DNA mutation, and apoptosis in aging. Exp Biol Med (Maywood) 232: 592-606. |
[28] |
Kwon MJ, Kim B, Lee YS, et al. (2012) Role of superoxide dismutase 3 in skin inflammation. J Dermatol Sci 67: 81-87. doi: 10.1016/j.jdermsci.2012.06.003
![]() |
[29] |
Kasapoglu M, Ozben T (2001) Alterations of antioxidant enzymes and oxidative stress markers in aging. Exp Gerontol 36: 209-220. doi: 10.1016/S0531-5565(00)00198-4
![]() |
[30] |
Marzani B, Felzani G, Bellomo RG, et al. (2005) Human muscle aging: ROS-mediated alterations in rectus abdominis and vastus lateralis muscles. Exp Gerontol 40: 959-965. doi: 10.1016/j.exger.2005.08.010
![]() |
[31] | Rodriguez-Capote K, Cespedes E, Arencibia R, et al. (1998) Indicators of oxidative stress in aging rat brain. The effect of nerve growth factor. Rev Neurol 27: 494-500. |
[32] |
Lu CY, Lee HC, Fahn HJ, et al. (1999) Oxidative damage elicited by imbalance of free radical scavenging enzymes is associated with large-scale mtDNA deletions in aging human skin. Mutat Res 423: 11-21. doi: 10.1016/S0027-5107(98)00220-6
![]() |
[33] |
Treiber N, Maity P, Singh K, et al. (2011) Accelerated aging phenotype in mice with conditional deficiency for mitochondrial superoxide dismutase in the connective tissue. Aging Cell 10: 239-254. doi: 10.1111/j.1474-9726.2010.00658.x
![]() |
[34] |
Mari M, Morales A, Colell A, et al. (2009) Mitochondrial glutathione, a key survival antioxidant. Antioxid Redox Signal 11: 2685-2700. doi: 10.1089/ars.2009.2695
![]() |
[35] |
Zhang H, Limphong P, Pieper J, et al. (2012) Glutathione-dependent reductive stress triggers mitochondrial oxidation and cytotoxicity. FASEB J 26: 1442-1451. doi: 10.1096/fj.11-199869
![]() |
[36] |
Gould NS, Min E, Gauthier S, et al. (2010) Aging adversely affects the cigarette smoke-induced glutathione adaptive response in the lung. Am J Respir Crit Care Med 182: 1114-1122. doi: 10.1164/rccm.201003-0442OC
![]() |
[37] | Doria E, Buonocore D, Focarelli A, et al. (2012) Relationship between human aging muscle and oxidative system pathway. Oxid Med Cell Longev 2012: 830257. |
[38] |
Myung SK, Ju W, Cho B, et al. (2013) Efficacy of vitamin and antioxidant supplements in prevention of cardiovascular disease: systematic review and meta-analysis of randomised controlled trials. BMJ 346: f10. doi: 10.1136/bmj.f10
![]() |
[39] |
Bjelakovic G, Nikolova D, Simonetti RG, et al. (2004) Antioxidant supplements for prevention of gastrointestinal cancers: a systematic review and meta-analysis. Lancet 364: 1219-1228. doi: 10.1016/S0140-6736(04)17138-9
![]() |
[40] |
Klotz LO, Sanchez-Ramos C, Prieto-Arroyo I, et al. (2015) Redox regulation of FoxO transcription factors. Redox Biol 6: 51-72. doi: 10.1016/j.redox.2015.06.019
![]() |
[41] |
Greer EL, Brunet A (2005) FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 24: 7410-7425. doi: 10.1038/sj.onc.1209086
![]() |
[42] |
Lin K, Dorman JB, Rodan A, et al. (1997) daf-16: An HNF-3/forkhead family member that can function to double the life-span of Caenorhabditis elegans. Science 278: 1319-1322. doi: 10.1126/science.278.5341.1319
![]() |
[43] |
Ogg S, Paradis S, Gottlieb S, et al. (1997) The Fork head transcription factor DAF-16 transduces insulin-like metabolic and longevity signals in C. elegans. Nature 389: 994-999. doi: 10.1038/40194
![]() |
[44] | Honda Y, Honda S (1999) The daf-2 gene network for longevity regulates oxidative stress resistance and Mn-superoxide dismutase gene expression in Caenorhabditis elegans. FASEB J 13: 1385-1393. |
[45] |
Kops GJ, Dansen TB, Polderman PE, et al. (2002) Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress. Nature 419: 316-321. doi: 10.1038/nature01036
![]() |
[46] |
van der Horst A, Burgering BM (2007) Stressing the role of FoxO proteins in lifespan and disease. Nat Rev Mol Cell Biol 8: 440-450. doi: 10.1038/nrm2190
![]() |
[47] |
Finkel T, Holbrook NJ (2000) Oxidants, oxidative stress and the biology of ageing. Nature 408: 239-247. doi: 10.1038/35041687
![]() |
[48] |
Honda Y, Honda S (2002) Oxidative stress and life span determination in the nematode Caenorhabditis elegans. Ann N Y Acad Sci 959: 466-474. doi: 10.1111/j.1749-6632.2002.tb02117.x
![]() |
[49] |
Ristow M, Schmeisser S (2011) Extending life span by increasing oxidative stress. Free Radic Biol Med 51: 327-336. doi: 10.1016/j.freeradbiomed.2011.05.010
![]() |
[50] |
Yoshioka T, Homma T, Meyrick B, et al. (1994) Oxidants induce transcriptional activation of manganese superoxide dismutase in glomerular cells. Kidney Int 46: 405-413. doi: 10.1038/ki.1994.288
![]() |
[51] |
Mesquita A, Weinberger M, Silva A, et al. (2010) Caloric restriction or catalase inactivation extends yeast chronological lifespan by inducing H2O2 and superoxide dismutase activity. Proc Natl Acad Sci U S A 107: 15123-15128. doi: 10.1073/pnas.1004432107
![]() |
[52] |
Yang W, Hekimi S (2010) A mitochondrial superoxide signal triggers increased longevity in Caenorhabditis elegans. PLoS Biol 8: e1000556. doi: 10.1371/journal.pbio.1000556
![]() |
[53] |
Schulz TJ, Zarse K, Voigt A, et al. (2007) Glucose restriction extends Caenorhabditis elegans life span by inducing mitochondrial respiration and increasing oxidative stress. Cell Metab 6: 280-293. doi: 10.1016/j.cmet.2007.08.011
![]() |
[54] |
Yun J, Finkel T (2014) Mitohormesis. Cell Metab 19: 757-766. doi: 10.1016/j.cmet.2014.01.011
![]() |
[55] | Yavari A, Javadi M, Mirmiran P, et al. (2015) Exercise-induced oxidative stress and dietary antioxidants. Asian J Sports Med 6: e24898. |
[56] |
Elchuri S, Oberley TD, Qi W, et al. (2005) CuZnSOD deficiency leads to persistent and widespread oxidative damage and hepatocarcinogenesis later in life. Oncogene 24: 367-380. doi: 10.1038/sj.onc.1208207
![]() |
[57] |
Schriner SE, Linford NJ, Martin GM, et al. (2005) Extension of murine life span by overexpression of catalase targeted to mitochondria. Science 308: 1909-1911. doi: 10.1126/science.1106653
![]() |
[58] |
Lopez-Otin C, Blasco MA, Partridge L, et al. (2013) The hallmarks of aging. Cell 153: 1194-1217. doi: 10.1016/j.cell.2013.05.039
![]() |
[59] |
Esposito L, Raber J, Kekonius L, et al. (2006) Reduction in mitochondrial superoxide dismutase modulates Alzheimer's disease-like pathology and accelerates the onset of behavioral changes in human amyloid precursor protein transgenic mice. J Neurosci 26: 5167-5179. doi: 10.1523/JNEUROSCI.0482-06.2006
![]() |
[60] |
Torzewski M, Ochsenhirt V, Kleschyov AL, et al. (2007) Deficiency of glutathione peroxidase-1 accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 27: 850-857. doi: 10.1161/01.ATV.0000258809.47285.07
![]() |
[61] | Salmon AB, Flores LC, Li Y, et al. (2012) Reduction of glucose intolerance with high fat feeding is associated with anti-inflammatory effects of thioredoxin 1 overexpression in mice. Pathobiol Aging Age Relat Dis 2: 89-97. |
[62] |
Shioji K, Kishimoto C, Nakamura H, et al. (2002) Overexpression of thioredoxin-1 in transgenic mice attenuates adriamycin-induced cardiotoxicity. Circulation 106: 1403-1409. doi: 10.1161/01.CIR.0000027817.55925.B4
![]() |
[63] |
Dizdaroglu M (2012) Oxidatively induced DNA damage: mechanisms, repair and disease. Cancer Lett 327: 26-47. doi: 10.1016/j.canlet.2012.01.016
![]() |
[64] |
Stadtman ER (2004) Role of oxidant species in aging. Curr Med Chem 11: 1105-1112. doi: 10.2174/0929867043365341
![]() |
[65] |
Yin H, Xu L, Porter NA (2011) Free radical lipid peroxidation: mechanisms and analysis. Chem Rev 111: 5944-5972. doi: 10.1021/cr200084z
![]() |
[66] |
de la Haba C, Palacio JR, Martinez P, et al. (2013) Effect of oxidative stress on plasma membrane fluidity of THP-1 induced macrophages. Biochim Biophys Acta 1828: 357-364. doi: 10.1016/j.bbamem.2012.08.013
![]() |
[67] |
Hayflick L, Moorhead PS (1961) The serial cultivation of human diploid cell strains. Exp Cell Res 25: 585-621. doi: 10.1016/0014-4827(61)90192-6
![]() |
[68] |
Dimri GP (2005) What has senescence got to do with cancer? Cancer Cell 7: 505-512. doi: 10.1016/j.ccr.2005.05.025
![]() |
[69] |
Tchkonia T, Zhu Y, van Deursen J, et al. (2013) Cellular senescence and the senescent secretory phenotype: therapeutic opportunities. J Clin Invest 123: 966-972. doi: 10.1172/JCI64098
![]() |
[70] |
Banito A, Lowe SW (2013) A new development in senescence. Cell 155: 977-978. doi: 10.1016/j.cell.2013.10.050
![]() |
[71] |
Munoz-Espin D, Canamero M, Maraver A, et al. (2013) Programmed Cell Senescence during Mammalian Embryonic Development. Cell 155: 1104-1118. doi: 10.1016/j.cell.2013.10.019
![]() |
[72] |
Storer M, Mas A, Robert-Moreno A, et al. (2013) Senescence is a developmental mechanism that contributes to embryonic growth and patterning. Cell 155: 1119-1130. doi: 10.1016/j.cell.2013.10.041
![]() |
[73] |
Bodnar AG, Ouellette M, Frolkis M, et al. (1998) Extension of life-span by introduction of telomerase into normal human cells. Science 279: 349-352. doi: 10.1126/science.279.5349.349
![]() |
[74] |
Tan FC, Hutchison ER, Eitan E, et al. (2014) Are there roles for brain cell senescence in aging and neurodegenerative disorders? Biogerontology 15: 643-660. doi: 10.1007/s10522-014-9532-1
![]() |
[75] |
Wang Z, Wei D, Xiao H (2013) Methods of cellular senescence induction using oxidative stress. Methods Mol Biol 1048: 135-144. doi: 10.1007/978-1-62703-556-9_11
![]() |
[76] |
Correia-Melo C, Hewitt G, Passos JF (2014) Telomeres, oxidative stress and inflammatory factors: partners in cellular senescence? Longev Healthspan 3: 1. doi: 10.1186/2046-2395-3-1
![]() |
[77] |
Hewitt G, Jurk D, Marques FD, et al. (2012) Telomeres are favoured targets of a persistent DNA damage response in ageing and stress-induced senescence. Nat Commun 3: 708. doi: 10.1038/ncomms1708
![]() |
[78] |
Itahana K, Campisi J, Dimri GP (2004) Mechanisms of cellular senescence in human and mouse cells. Biogerontology 5: 1-10. doi: 10.1023/B:BGEN.0000017682.96395.10
![]() |
[79] |
Dimri GP, Lee X, Basile G, et al. (1995) A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A 92: 9363-9367. doi: 10.1073/pnas.92.20.9363
![]() |
[80] |
Narita M, Nunez S, Heard E, et al. (2003) Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 113: 703-716. doi: 10.1016/S0092-8674(03)00401-X
![]() |
[81] |
Alcorta DA, Xiong Y, Phelps D, et al. (1996) Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts. Proc Natl Acad Sci U S A 93: 13742-13747. doi: 10.1073/pnas.93.24.13742
![]() |
[82] |
Hara E, Smith R, Parry D, et al. (1996) Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence. Mol Cell Biol 16: 859-867. doi: 10.1128/MCB.16.3.859
![]() |
[83] | Coppe JP, Patil CK, Rodier F, et al. (2008) Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol 6: 2853-2868. |
[84] |
Coppe JP, Desprez PY, Krtolica A, et al. (2010) The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol 5: 99-118. doi: 10.1146/annurev-pathol-121808-102144
![]() |
[85] |
Coppe JP, Rodier F, Patil CK, et al. (2011) Tumor suppressor and aging biomarker p16(INK4a) induces cellular senescence without the associated inflammatory secretory phenotype. J Biol Chem 286: 36396-36403. doi: 10.1074/jbc.M111.257071
![]() |
[86] |
Chen Q, Fischer A, Reagan JD, et al. (1995) Oxidative DNA damage and senescence of human diploid fibroblast cells. Proc Natl Acad Sci U S A 92: 4337-4341. doi: 10.1073/pnas.92.10.4337
![]() |
[87] |
Parrinello S, Samper E, Krtolica A, et al. (2003) Oxygen sensitivity severely limits the replicative lifespan of murine fibroblasts. Nat Cell Biol 5: 741-747. doi: 10.1038/ncb1024
![]() |
[88] |
Colavitti R, Finkel T (2005) Reactive oxygen species as mediators of cellular senescence. IUBMB Life 57: 277-281. doi: 10.1080/15216540500091890
![]() |
[89] |
d'Adda di Fagagna F, Reaper PM, Clay-Farrace L, et al. (2003) A DNA damage checkpoint response in telomere-initiated senescence. Nature 426: 194-198. doi: 10.1038/nature02118
![]() |
[90] |
Di Micco R, Fumagalli M, Cicalese A, et al. (2006) Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 444: 638-642. doi: 10.1038/nature05327
![]() |
[91] | Passos JF, Nelson G, Wang C, et al. (2010) Feedback between p21 and reactive oxygen production is necessary for cell senescence. Mol Syst Biol 6: 347. |
[92] |
Wiley CD, Velarde MC, Lecot P, et al. (2016) Mitochondrial Dysfunction Induces Senescence with a Distinct Secretory Phenotype. Cell Metab 23: 303-314. doi: 10.1016/j.cmet.2015.11.011
![]() |
[93] |
Bracken AP, Kleine-Kohlbrecher D, Dietrich N, et al. (2007) The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells. Genes Dev 21: 525-530. doi: 10.1101/gad.415507
![]() |
[94] |
Liu J, Cao L, Chen J, et al. (2009) Bmi1 regulates mitochondrial function and the DNA damage response pathway. Nature 459: 387-392. doi: 10.1038/nature08040
![]() |
[95] |
Itahana K, Zou Y, Itahana Y, et al. (2003) Control of the replicative life span of human fibroblasts by p16 and the polycomb protein Bmi-1. Mol Cell Biol 23: 389-401. doi: 10.1128/MCB.23.1.389-401.2003
![]() |
[96] |
Acosta JC, Banito A, Wuestefeld T, et al. (2013) A complex secretory program orchestrated by the inflammasome controls paracrine senescence. Nat Cell Biol 15: 978-990. doi: 10.1038/ncb2784
![]() |
[97] |
Kuilman T, Peeper DS (2009) Senescence-messaging secretome: SMS-ing cellular stress. Nat Rev Cancer 9: 81-94. doi: 10.1038/nrc2560
![]() |
[98] |
Passos JF, von Zglinicki T (2005) Mitochondria, telomeres and cell senescence. Exp Gerontol 40: 466-472. doi: 10.1016/j.exger.2005.04.006
![]() |
[99] |
Balaban RS, Nemoto S, Finkel T (2005) Mitochondria, oxidants, and aging. Cell 120: 483-495. doi: 10.1016/j.cell.2005.02.001
![]() |
[100] |
Correia-Melo C, Marques FD, Anderson R, et al. (2016) Mitochondria are required for pro-ageing features of the senescent phenotype. EMBO J 35: 724-742. doi: 10.15252/embj.201592862
![]() |
[101] |
Ziegler DV, Wiley CD, Velarde MC (2015) Mitochondrial effectors of cellular senescence: beyond the free radical theory of aging. Aging Cell 14: 1-7. doi: 10.1111/acel.12287
![]() |
[102] |
Gomes AP, Price NL, Ling AJ, et al. (2013) Declining NAD(+) induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Cell 155: 1624-1638. doi: 10.1016/j.cell.2013.11.037
![]() |
[103] |
Mouchiroud L, Houtkooper RH, Moullan N, et al. (2013) The NAD(+)/Sirtuin Pathway Modulates Longevity through Activation of Mitochondrial UPR and FOXO Signaling. Cell 154: 430-441. doi: 10.1016/j.cell.2013.06.016
![]() |
[104] |
Canto C, Gerhart-Hines Z, Feige JN, et al. (2009) AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature 458: 1056-1060. doi: 10.1038/nature07813
![]() |
[105] |
Ruderman NB, Xu XJ, Nelson L, et al. (2010) AMPK and SIRT1: a long-standing partnership? Am J Physiol Endocrinol Metab 298: E751-760. doi: 10.1152/ajpendo.00745.2009
![]() |
[106] |
Price NL, Gomes AP, Ling AJ, et al. (2012) SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab 15: 675-690. doi: 10.1016/j.cmet.2012.04.003
![]() |
[107] | Zhang H, Ryu D, Wu Y, et al. (2016) NAD+ repletion improves mitochondrial and stem cell function and enhances life span in mice. Science in press. |
[108] |
Baker DJ, Wijshake T, Tchkonia T, et al. (2011) Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature 479: 232-236. doi: 10.1038/nature10600
![]() |
[109] |
Campisi J (2013) Aging, cellular senescence, and cancer. Annu Rev Physiol 75: 685-705. doi: 10.1146/annurev-physiol-030212-183653
![]() |
[110] |
Collado M, Blasco MA, Serrano M (2007) Cellular senescence in cancer and aging. Cell 130: 223-233. doi: 10.1016/j.cell.2007.07.003
![]() |
[111] |
Naylor RM, Baker DJ, van Deursen JM (2013) Senescent cells: a novel therapeutic target for aging and age-related diseases. Clin Pharmacol Ther 93: 105-116. doi: 10.1038/clpt.2012.193
![]() |
[112] |
Childs BG, Durik M, Baker DJ, et al. (2015) Cellular senescence in aging and age-related disease: from mechanisms to therapy. Nat Med 21: 1424-1435. doi: 10.1038/nm.4000
![]() |
[113] |
Passos JF, Saretzki G, Ahmed S, et al. (2007) Mitochondrial dysfunction accounts for the stochastic heterogeneity in telomere-dependent senescence. PLoS Biol 5: e110. doi: 10.1371/journal.pbio.0050110
![]() |
[114] |
Blackburn EH, Epel ES, Lin J (2015) Human telomere biology: A contributory and interactive factor in aging, disease risks, and protection. Science 350: 1193-1198. doi: 10.1126/science.aab3389
![]() |
[115] |
Fyhrquist F, Saijonmaa O, Strandberg T (2013) The roles of senescence and telomere shortening in cardiovascular disease. Nat Rev Cardiol 10: 274-283. doi: 10.1038/nrcardio.2013.30
![]() |
[116] |
Minamino T, Miyauchi H, Yoshida T, et al. (2004) The role of vascular cell senescence in atherosclerosis: antisenescence as a novel therapeutic strategy for vascular aging. Curr Vasc Pharmacol 2: 141-148. doi: 10.2174/1570161043476393
![]() |
[117] |
Navab M, Berliner JA, Watson AD, et al. (1996) The Yin and Yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture. Arterioscler Thromb Vasc Biol 16: 831-842. doi: 10.1161/01.ATV.16.7.831
![]() |
[118] |
Csiszar A, Wang M, Lakatta EG, et al. (2008) Inflammation and endothelial dysfunction during aging: role of NF-kappaB. J Appl Physiol (1985) 105: 1333-1341. doi: 10.1152/japplphysiol.90470.2008
![]() |
[119] |
Acosta JC, O'Loghlen A, Banito A, et al. (2008) Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell 133: 1006-1018. doi: 10.1016/j.cell.2008.03.038
![]() |
[120] |
Chien Y, Scuoppo C, Wang X, et al. (2011) Control of the senescence-associated secretory phenotype by NF-kappaB promotes senescence and enhances chemosensitivity. Genes Dev 25: 2125-2136. doi: 10.1101/gad.17276711
![]() |
[121] |
Freund A, Patil CK, Campisi J (2011) p38MAPK is a novel DNA damage response-independent regulator of the senescence-associated secretory phenotype. EMBO J 30: 1536-1548. doi: 10.1038/emboj.2011.69
![]() |
[122] | Mowla SN, Perkins ND, Jat PS (2013) Friend or foe: emerging role of nuclear factor kappa-light-chain-enhancer of activated B cells in cell senescence. Onco Targets Ther 6: 1221-1229. |
[123] |
Eren M, Boe AE, Murphy SB, et al. (2014) PAI-1-regulated extracellular proteolysis governs senescence and survival in Klotho mice. Proc Natl Acad Sci U S A 111: 7090-7095. doi: 10.1073/pnas.1321942111
![]() |
[124] | Kuro-o M (2008) Klotho as a regulator of oxidative stress and senescence. Biol Chem 389: 233-241. |
[125] |
Sato S, Kawamata Y, Takahashi A, et al. (2015) Ablation of the p16(INK4a) tumour suppressor reverses ageing phenotypes of klotho mice. Nat Commun 6: 7035. doi: 10.1038/ncomms8035
![]() |
[126] |
Maekawa Y, Ishikawa K, Yasuda O, et al. (2009) Klotho suppresses TNF-alpha-induced expression of adhesion molecules in the endothelium and attenuates NF-kappaB activation. Endocrine 35: 341-346. doi: 10.1007/s12020-009-9181-3
![]() |
[127] |
Luzi L, Confalonieri S, Di Fiore PP, et al. (2000) Evolution of Shc functions from nematode to human. Curr Opin Genet Dev 10: 668-674. doi: 10.1016/S0959-437X(00)00146-5
![]() |
[128] |
Migliaccio E, Giorgio M, Mele S, et al. (1999) The p66shc adaptor protein controls oxidative stress response and life span in mammals. Nature 402: 309-313. doi: 10.1038/46311
![]() |
[129] |
Suski JM, Karkucinska-Wieckowska A, Lebiedzinska M, et al. (2011) p66Shc aging protein in control of fibroblasts cell fate. Int J Mol Sci 12: 5373-5389. doi: 10.3390/ijms12085373
![]() |
[130] |
Franzeck FC, Hof D, Spescha RD, et al. (2012) Expression of the aging gene p66Shc is increased in peripheral blood monocytes of patients with acute coronary syndrome but not with stable coronary artery disease. Atherosclerosis 220: 282-286. doi: 10.1016/j.atherosclerosis.2011.10.035
![]() |
[131] |
Cosentino F, Francia P, Camici GG, et al. (2008) Final common molecular pathways of aging and cardiovascular disease: role of the p66Shc protein. Arterioscler Thromb Vasc Biol 28: 622-628. doi: 10.1161/ATVBAHA.107.156059
![]() |
[132] |
Carpi A, Menabo R, Kaludercic N, et al. (2009) The cardioprotective effects elicited by p66(Shc) ablation demonstrate the crucial role of mitochondrial ROS formation in ischemia/reperfusion injury. Biochim Biophys Acta 1787: 774-780. doi: 10.1016/j.bbabio.2009.04.001
![]() |
[133] |
Morley JE, Armbrecht HJ, Farr SA, et al. (2012) The senescence accelerated mouse (SAMP8) as a model for oxidative stress and Alzheimer's disease. Biochim Biophys Acta 1822: 650-656. doi: 10.1016/j.bbadis.2011.11.015
![]() |
[134] | Nunomura A, Perry G, Aliev G, et al. (2001) Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 60: 759-767. |
[135] |
Karran E, Mercken M, De Strooper B (2011) The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov 10: 698-712. doi: 10.1038/nrd3505
![]() |
[136] | Casley CS, Canevari L, Land JM, et al. (2002) Beta-amyloid inhibits integrated mitochondrial respiration and key enzyme activities. J Neurochem 80: 91-100. |
[137] | Swerdlow RH, Burns JM, Khan SM (2010) The Alzheimer's disease mitochondrial cascade hypothesis. J Alzheimers Dis 20 Suppl 2: S265-279. |
[138] |
Bhat R, Crowe EP, Bitto A, et al. (2012) Astrocyte senescence as a component of Alzheimer's disease. PLoS One 7: e45069. doi: 10.1371/journal.pone.0045069
![]() |
[139] |
Streit WJ, Xue QS (2009) Life and death of microglia. J Neuroimmune Pharmacol 4: 371-379. doi: 10.1007/s11481-009-9163-5
![]() |
[140] |
Boccardi V, Pelini L, Ercolani S, et al. (2015) From cellular senescence to Alzheimer's disease: The role of telomere shortening. Ageing Res Rev 22: 1-8. doi: 10.1016/j.arr.2015.04.003
![]() |
[141] |
Dawson TM, Ko HS, Dawson VL (2010) Genetic animal models of Parkinson's disease. Neuron 66: 646-661. doi: 10.1016/j.neuron.2010.04.034
![]() |
[142] |
Ahlskog JE (2005) Challenging conventional wisdom: the etiologic role of dopamine oxidative stress in Parkinson's disease. Mov Disord 20: 271-282. doi: 10.1002/mds.20362
![]() |
[143] |
Ohtsuka C, Sasaki M, Konno K, et al. (2013) Changes in substantia nigra and locus coeruleus in patients with early-stage Parkinson's disease using neuromelanin-sensitive MR imaging. Neurosci Lett 541: 93-98. doi: 10.1016/j.neulet.2013.02.012
![]() |
[144] | Hattingen E, Magerkurth J, Pilatus U, et al. (2009) Phosphorus and proton magnetic resonance spectroscopy demonstrates mitochondrial dysfunction in early and advanced Parkinson's disease. Brain 132: 3285-3297. |
[145] |
Srinivasan V, Cardinali DP, Srinivasan US, et al. (2011) Therapeutic potential of melatonin and its analogs in Parkinson's disease: focus on sleep and neuroprotection. Ther Adv Neurol Disord 4: 297-317. doi: 10.1177/1756285611406166
![]() |
[146] |
Corti O, Lesage S, Brice A (2011) What genetics tells us about the causes and mechanisms of Parkinson's disease. Physiol Rev 91: 1161-1218. doi: 10.1152/physrev.00022.2010
![]() |
[147] |
Perfeito R, Cunha-Oliveira T, Rego AC (2012) Revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease--resemblance to the effect of amphetamine drugs of abuse. Free Radic Biol Med 53: 1791-1806. doi: 10.1016/j.freeradbiomed.2012.08.569
![]() |
[148] |
Chinta SJ, Lieu CA, Demaria M, et al. (2013) Environmental stress, ageing and glial cell senescence: a novel mechanistic link to Parkinson's disease? J Intern Med 273: 429-436. doi: 10.1111/joim.12029
![]() |
[149] |
Palmer AK, Tchkonia T, LeBrasseur NK, et al. (2015) Cellular Senescence in Type 2 Diabetes: A Therapeutic Opportunity. Diabetes 64: 2289-2298. doi: 10.2337/db14-1820
![]() |
[150] |
Ksiazek K, Passos JF, Olijslagers S, et al. (2008) Mitochondrial dysfunction is a possible cause of accelerated senescence of mesothelial cells exposed to high glucose. Biochem Biophys Res Commun 366: 793-799. doi: 10.1016/j.bbrc.2007.12.021
![]() |
[151] |
Tchkonia T, Morbeck DE, Von Zglinicki T, et al. (2010) Fat tissue, aging, and cellular senescence. Aging Cell 9: 667-684. doi: 10.1111/j.1474-9726.2010.00608.x
![]() |
[152] |
Moiseeva O, Deschenes-Simard X, St-Germain E, et al. (2013) Metformin inhibits the senescence-associated secretory phenotype by interfering with IKK/NF-kappaB activation. Aging Cell 12: 489-498. doi: 10.1111/acel.12075
![]() |
[153] | Martin-Montalvo A, Mercken EM, Mitchell SJ, et al. (2013) Metformin improves healthspan and lifespan in mice. Nat Commun 4: 2192. |
[154] | Glasauer A, Chandel NS (2014) Targeting antioxidants for cancer therapy. Biochem Pharmacol 92: 90-101. |
[155] |
Reuter S, Gupta SC, Chaturvedi MM, et al. (2010) Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med 49: 1603-1616. doi: 10.1016/j.freeradbiomed.2010.09.006
![]() |
[156] |
Trachootham D, Alexandre J, Huang P (2009) Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov 8: 579-591. doi: 10.1038/nrd2803
![]() |
[157] |
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674. doi: 10.1016/j.cell.2011.02.013
![]() |
[158] |
Collado M, Serrano M (2010) Senescence in tumours: evidence from mice and humans. Nat Rev Cancer 10: 51-57. doi: 10.1038/nrc2772
![]() |
[159] |
Campisi J (2011) Cellular senescence: putting the paradoxes in perspective. Curr Opin Genet Dev 21: 107-112. doi: 10.1016/j.gde.2010.10.005
![]() |
[160] |
Krtolica A, Parrinello S, Lockett S, et al. (2001) Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc Natl Acad Sci U S A 98: 12072-12077. doi: 10.1073/pnas.211053698
![]() |
[161] |
Davalos AR, Coppe JP, Campisi J, et al. (2010) Senescent cells as a source of inflammatory factors for tumor progression. Cancer Metastasis Rev 29: 273-283. doi: 10.1007/s10555-010-9220-9
![]() |
[162] |
Sun Y, Campisi J, Higano C, et al. (2012) Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat Med 18: 1359-1368. doi: 10.1038/nm.2890
![]() |
[163] |
Achuthan S, Santhoshkumar TR, Prabhakar J, et al. (2011) Drug-induced senescence generates chemoresistant stemlike cells with low reactive oxygen species. J Biol Chem 286: 37813-37829. doi: 10.1074/jbc.M110.200675
![]() |
[164] |
Cahu J, Bustany S, Sola B (2012) Senescence-associated secretory phenotype favors the emergence of cancer stem-like cells. Cell Death Dis 3: e446. doi: 10.1038/cddis.2012.183
![]() |
[165] |
Hoare M, Narita M (2013) Transmitting senescence to the cell neighbourhood. Nat Cell Biol 15: 887-889. doi: 10.1038/ncb2811
![]() |
[166] |
Krishnamurthy J, Torrice C, Ramsey MR, et al. (2004) Ink4a/Arf expression is a biomarker of aging. J Clin Invest 114: 1299-1307. doi: 10.1172/JCI22475
![]() |
[167] |
Sharpless NE, Sherr CJ (2015) Forging a signature of in vivo senescence. Nat Rev Cancer 15: 397-408. doi: 10.1038/nrc3960
![]() |
[168] |
Burd CE, Sorrentino JA, Clark KS, et al. (2013) Monitoring tumorigenesis and senescence in vivo with a p16(INK4a)-luciferase model. Cell 152: 340-351. doi: 10.1016/j.cell.2012.12.010
![]() |
[169] |
Demaria M, Ohtani N, Youssef SA, et al. (2014) An essential role for senescent cells in optimal wound healing through secretion of PDGF-AA. Dev Cell 31: 722-733. doi: 10.1016/j.devcel.2014.11.012
![]() |
[170] |
Cheng S, Rodier F (2015) Manipulating senescence in health and disease: emerging tools. Cell Cycle 14: 1613-1614. doi: 10.1080/15384101.2015.1039359
![]() |
[171] |
Baker DJ, Childs BG, Durik M, et al. (2016) Naturally occurring p16(Ink4a)-positive cells shorten healthy lifespan. Nature 530: 184-189. doi: 10.1038/nature16932
![]() |
[172] | Xu M, Palmer AK, Ding H, et al. (2015) Targeting senescent cells enhances adipogenesis and metabolic function in old age. Elife 4: e12997. |
[173] |
Xu M, Tchkonia T, Ding H, et al. (2015) JAK inhibition alleviates the cellular senescence-associated secretory phenotype and frailty in old age. Proc Natl Acad Sci U S A 112: E6301-6310. doi: 10.1073/pnas.1515386112
![]() |
[174] |
Zhu Y, Tchkonia T, Pirtskhalava T, et al. (2015) The Achilles' heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell 14: 644-658. doi: 10.1111/acel.12344
![]() |
[175] | Chang J, Wang Y, Shao L, et al. (2016) Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nat Med 22: 78-83. |
[176] |
Yosef R, Pilpel N, Tokarsky-Amiel R, et al. (2016) Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL. Nat Commun 7: 11190. doi: 10.1038/ncomms11190
![]() |
1. | Michela Roberto, Paolo Marchetti, Giulia Arrivi, Francesca Romana Di Pietro, Stefano Cascinu, Fabio Gelsomino, Francesco Caputo, Krisida Cerma, Michele Ghidini, Margherita Ratti, Claudio Pizzo, Corrado Ficorella, Alessandro Parisi, Alessio Cortellini, Federica Urbano, Maria Letizia Calandrella, Andrea Botticelli, Emanuela Dell’Aquila, Alessandro Minelli, Claudia Fulgenzi, Andrea Montori, Emanuela Pilozzi, Federica Mazzuca, The treatment paradigm of right-sided metastatic colon cancer: harboring BRAF mutation makes the difference, 2020, 35, 0179-1958, 1513, 10.1007/s00384-020-03589-9 | |
2. | Krasimir Petrov, Ivan Ivanov, Savelina Popovska, Tatyana Betova, Zornitsa Kamburova, Colorectal Cancer: A Brief and Simplified Analysis of a Complex Disease, 2024, 60, 1648-9144, 2034, 10.3390/medicina60122034 |
Trial | Left colon cancer OS (months) |
HR, 95% CI p value |
Right colon cancer OS (months) |
HR, 95% CI p value |
||
CALGB 80405 | Overall pop = 32.9 | Overall pop = 19.6 (p < 0.0001) | ||||
Chemo + Cet | Chemo + Bev | Chemo + Cet | Chemo + Bev | |||
39.3 | 32.6 | 0.77 (0.59-0.99) p = 0.05 |
13.7 | 29.2 | 1.36 (0.93-1.99) p = 0.11 |
|
FIRE-3 | 38.3 | 28.0 | 0.63 (0.48-0.85) p = 0.002 |
18.3 | 23.0 | 1.31 (0.81-2.11) p = 0.27 |
FOLFIRI + Cet | FOLFIRI only | FOLFIRI + Cet | FOLFIRI only | |||
CRYSTAL | 28.7 | 21.7 | 0.65 (0.50-0.86) p = 0.002 |
18.5 | 15.0 | 1.08 (0.65-1.81) p = 0.77 |
FOLFOX + Pani | FOLFOX only | FOLFOX + Pani | FOLFOX only | |||
PRIME | 30.3 | 23.6 | 0.73 (0.57-0.93) p = 0.012 |
11.1 | 15.4 | 0.87 (0.55-1.37) p = 0.55 |
FOLFOX + Pani | FOLFOX + Bev | FOLFOX + Pani | FOLFOX + Bev | |||
PEAK | 43.4 | 32.0 | 0.77 (0.46-1.28) p = 0.31 |
17.4 | 21.0 | 0.67 (0.30-1.50) p = 0.32 |
Cet: Cetuximab; Pani: Panitumumab; Bev: Bevacizumab; OS: Overall survival; HR: Hazard ratio. |
Author | Number of patients | Year of pub. | 5 yr OS (R v L) | Median OS (R v L) in months | Risk of death as HR (95% CI) |
Benedix | 17,000 | 2010 | 67% v 71% (p < 0.01) | ||
Meguid | 78,000 | 2008 | 56% v 60% (p < 0.001) | 78 v 89 (p < 0.001) | 0.96 (0.93-0.99) |
Price | 2,900 | 2015 | 9.6 v 20.3 (p < 0.0001) | ||
Petrelli | 1.4 Million | 2017 | 0.82 (0.79-0.84) |
Trial | Left colon cancer OS (months) |
HR, 95% CI p value |
Right colon cancer OS (months) |
HR, 95% CI p value |
||
CALGB 80405 | Overall pop = 32.9 | Overall pop = 19.6 (p < 0.0001) | ||||
Chemo + Cet | Chemo + Bev | Chemo + Cet | Chemo + Bev | |||
39.3 | 32.6 | 0.77 (0.59-0.99) p = 0.05 |
13.7 | 29.2 | 1.36 (0.93-1.99) p = 0.11 |
|
FIRE-3 | 38.3 | 28.0 | 0.63 (0.48-0.85) p = 0.002 |
18.3 | 23.0 | 1.31 (0.81-2.11) p = 0.27 |
FOLFIRI + Cet | FOLFIRI only | FOLFIRI + Cet | FOLFIRI only | |||
CRYSTAL | 28.7 | 21.7 | 0.65 (0.50-0.86) p = 0.002 |
18.5 | 15.0 | 1.08 (0.65-1.81) p = 0.77 |
FOLFOX + Pani | FOLFOX only | FOLFOX + Pani | FOLFOX only | |||
PRIME | 30.3 | 23.6 | 0.73 (0.57-0.93) p = 0.012 |
11.1 | 15.4 | 0.87 (0.55-1.37) p = 0.55 |
FOLFOX + Pani | FOLFOX + Bev | FOLFOX + Pani | FOLFOX + Bev | |||
PEAK | 43.4 | 32.0 | 0.77 (0.46-1.28) p = 0.31 |
17.4 | 21.0 | 0.67 (0.30-1.50) p = 0.32 |
Cet: Cetuximab; Pani: Panitumumab; Bev: Bevacizumab; OS: Overall survival; HR: Hazard ratio. |
Author | Number of patients | Year of pub. | 5 yr OS (R v L) | Median OS (R v L) in months | Risk of death as HR (95% CI) |
Benedix | 17,000 | 2010 | 67% v 71% (p < 0.01) | ||
Meguid | 78,000 | 2008 | 56% v 60% (p < 0.001) | 78 v 89 (p < 0.001) | 0.96 (0.93-0.99) |
Price | 2,900 | 2015 | 9.6 v 20.3 (p < 0.0001) | ||
Petrelli | 1.4 Million | 2017 | 0.82 (0.79-0.84) |